Regeneron Pharmaceuticals Inc (REGN) Receives $394.19 Consensus Target Price from Analysts

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been assigned an average recommendation of “Hold” from the twenty-five research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $399.93.

Several equities analysts have recently weighed in on the company. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, January 7th. Cowen restated a “hold” rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, January 7th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, January 5th. Guggenheim upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price objective for the company in a report on Friday, January 4th. Finally, ValuEngine upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 15th.

REGN stock traded up $0.57 during trading hours on Friday, reaching $408.63. 755,441 shares of the stock were exchanged, compared to its average volume of 850,080. The stock has a market cap of $43.24 billion, a PE ratio of 30.47, a price-to-earnings-growth ratio of 1.72 and a beta of 1.14. The company has a current ratio of 4.04, a quick ratio of 3.30 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $281.89 and a 12 month high of $416.49.



Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.94 by $0.93. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.99 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post 18.88 earnings per share for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 1,791 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at $5,786,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the transaction, the vice president now owns 9,871 shares of the company’s stock, valued at approximately $3,543,392.87. The disclosure for this sale can be found here. Insiders have sold 3,645 shares of company stock valued at $1,399,980 in the last quarter. 12.42% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. First Hawaiian Bank grew its holdings in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. First Hawaiian Bank now owns 3,961 shares of the biopharmaceutical company’s stock worth $1,479,000 after purchasing an additional 346 shares during the period. Pensionfund DSM Netherlands acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $2,502,000. Pensionfund Sabic acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $1,868,000. Nordea Investment Management AB lifted its position in Regeneron Pharmaceuticals by 1.5% during the third quarter. Nordea Investment Management AB now owns 4,215 shares of the biopharmaceutical company’s stock worth $1,703,000 after acquiring an additional 64 shares during the last quarter. Finally, Vanguard Group Inc lifted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after acquiring an additional 75,868 shares during the last quarter. Institutional investors and hedge funds own 67.20% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: What are no-load funds?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply